Cite
Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States.
MLA
Rhodes, Nathaniel J., et al. “Multicenter Point Prevalence Evaluation of the Utilization and Safety of Drug Therapies for COVID-19 at the Onset of the Pandemic Timeline in the United States.” American Journal of Health-System Pharmacy, vol. 78, no. 7, Apr. 2021, pp. 568–77. EBSCOhost, https://doi.org/10.1093/ajhp/zxaa426.
APA
Rhodes, N. J., Dairem, A., Moore, W. J., Shah, A., Postelnick, M. J., Badowski, M. E., Michienzi, S. M., Borkowski, J. L., Polisetty, R. S., Fong, K., Spivak, E. S., Beardsley, J. R., Hale, C. M., Pallotta, A. M., Srinivas, P., & Schulz, L. T. (2021). Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. American Journal of Health-System Pharmacy, 78(7), 568–577. https://doi.org/10.1093/ajhp/zxaa426
Chicago
Rhodes, Nathaniel J, Atheer Dairem, William J Moore, Anooj Shah, Michael J Postelnick, Melissa E Badowski, Sarah M Michienzi, et al. 2021. “Multicenter Point Prevalence Evaluation of the Utilization and Safety of Drug Therapies for COVID-19 at the Onset of the Pandemic Timeline in the United States.” American Journal of Health-System Pharmacy 78 (7): 568–77. doi:10.1093/ajhp/zxaa426.